钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂类药物的风险与益处
Risks vs Benefits for SGLT2 Inhibitor Medications.
作者信息
Pittampalli Shanti, Upadyayula Satya, Mekala Hema Madhuri, Lippmann Steven
机构信息
is a Resident at Mercy Saint Vincent Medical Center in Toledo, Ohio. is a Research Scholar, and is an Emeritus Professor, both at the University of Louisville in Kentucky. is a Resident at the Griffin Memorial Hospital in Norman, Oklahoma.
出版信息
Fed Pract. 2018 Jul;35(7):45-48.
Abstract
Health care providers should carefully assess patients with diabetes mellitus before prescribing sodium-glucose cotransporter 2 inhibitor medications and monitor for adverse effects.
摘要
医疗保健提供者在开处方使用钠-葡萄糖协同转运蛋白2抑制剂药物之前，应仔细评估糖尿病患者，并监测不良反应。
相似文献
1
Risks vs Benefits for SGLT2 Inhibitor Medications.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂类药物的风险与益处
Fed Pract. 2018 Jul;35(7):45-48.
2
Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.与钠-葡萄糖协同转运蛋白2抑制剂使用相关的正常血糖性糖尿病酮症酸中毒：一例病例报告及文献综述
Int J Emerg Med. 2019 Sep 5;12(1):27. doi: 10.1186/s12245-019-0240-0.
3
Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.二肽基肽酶-4抑制剂与钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病联合治疗中的临床应用
Postgrad Med. 2015 Jun;127(5):463-79. doi: 10.1080/00325481.2015.1044756. Epub 2015 May 8.
4
Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂的肾脏和心脏影响：科学现状。
Ann Pharmacother. 2018 Dec;52(12):1238-1249. doi: 10.1177/1060028018783661. Epub 2018 Jun 17.
5
An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients.钠葡萄糖协同转运蛋白2抑制剂单药治疗对2型糖尿病患者血糖及其他临床实验室参数影响的综述
Ther Clin Risk Manag. 2016 Jul 15;12:1113-31. doi: 10.2147/TCRM.S112236. eCollection 2016.
6
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂对 2 型糖尿病成人患者心血管事件、死亡和主要安全性结局的影响：系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2016 May;4(5):411-9. doi: 10.1016/S2213-8587(16)00052-8. Epub 2016 Mar 18.
7
Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂单药治疗对 2 型糖尿病患者体重变化的影响：一项贝叶斯网状 Meta 分析。
Clin Ther. 2019 Feb;41(2):322-334.e11. doi: 10.1016/j.clinthera.2019.01.001. Epub 2019 Jan 30.
8
Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.钠-葡萄糖协同转运蛋白2抑制剂所致急性肾衰竭：美国食品药品监督管理局不良事件报告系统数据库分析
Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1108-1113. doi: 10.1016/j.numecd.2017.10.011. Epub 2017 Oct 18.
9
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents.天然产物来源的钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：新一代降血糖药物的发现
Molecules. 2016 Aug 27;21(9):1136. doi: 10.3390/molecules21091136.
10
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.在 2 型糖尿病中使用 SGLT2 抑制剂：权衡风险与获益。
Diabetologia. 2018 Oct;61(10):2118-2125. doi: 10.1007/s00125-018-4663-6. Epub 2018 Aug 22.
引用本文的文献
1
A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.2型糖尿病和心血管疾病十年进展：钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂的进展——综述
Front Endocrinol (Lausanne). 2025 Jul 7;16:1605746. doi: 10.3389/fendo.2025.1605746. eCollection 2025.
2
Mechanistic underpinnings of AGEs-RAGE via DIAPH1 in ischemic, diabetic, and failing hearts.晚期糖基化终末产物受体（RAGE）通过DIAPH1在缺血性、糖尿病性和衰竭心脏中的作用机制。
Am J Physiol Heart Circ Physiol. 2025 Mar 25. doi: 10.1152/ajpheart.00685.2024.
3
SGLT-2 Inhibitors as an Effective Treatment for Type 2 Diabetes Mellitus, Hypertension, and Hyperuricemia - A Mechanistic Perspective.从机制角度看，钠-葡萄糖协同转运蛋白2抑制剂作为2型糖尿病、高血压和高尿酸血症的有效治疗方法
Curr Drug Saf. 2025;20(4):399-401. doi: 10.2174/0115748863344964241106051256.
4
Increased risk of adverse events among patients with vs. without systemic autoimmune rheumatic disease prescribed sodium-glucose cotransporter 2 inhibitors: a retrospective cohort study.与未使用钠-葡萄糖共转运蛋白 2 抑制剂的患者相比，使用该药物的系统性自身免疫性风湿病患者发生不良事件的风险增加：一项回顾性队列研究。
Clin Rheumatol. 2024 Dec;43(12):3839-3847. doi: 10.1007/s10067-024-07206-w. Epub 2024 Oct 25.
5
Strategies to address diabetic kidney disease burden in Mexico: a narrative review by the Mexican College of Nephrologists.应对墨西哥糖尿病肾病负担的策略：墨西哥肾脏病学会的叙述性综述
Front Med (Lausanne). 2024 Jun 19;11:1376115. doi: 10.3389/fmed.2024.1376115. eCollection 2024.
6
Empagliflozin-Associated Pancreatitis in the Setting of Hyperglycemic Hyperosmolar Syndrome.在高血糖高渗综合征背景下与恩格列净相关的胰腺炎
Cureus. 2024 May 23;16(5):e60935. doi: 10.7759/cureus.60935. eCollection 2024 May.
7
Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus.糖尿病与中风：2型糖尿病新型治疗方法的影响
Biomedicines. 2024 May 16;12(5):1102. doi: 10.3390/biomedicines12051102.
8
Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂、二肽基肽酶-4（DPP-4）抑制剂和二甲双胍在胰腺癌预防中的作用
Cancers (Basel). 2024 Mar 28;16(7):1325. doi: 10.3390/cancers16071325.
9
Vitamin D for glycemic control following an acute pulmonary exacerbation: A secondary analysis of a multicenter, double-blind, randomized, placebo-controlled trial in adults with cystic fibrosis.急性肺部加重期后维生素D对血糖控制的影响：一项针对成年囊性纤维化患者的多中心、双盲、随机、安慰剂对照试验的二次分析
medRxiv. 2024 Mar 10:2024.01.04.24300862. doi: 10.1101/2024.01.04.24300862.
10
A low-carbohydrate diet in place of SGLT2i therapy in a patient with diabetic cardiomyopathy.用低碳水化合物饮食替代糖尿病性心肌病患者的SGLT2i治疗。
Endocrinol Diabetes Metab Case Rep. 2023 Dec 13;2023(4). doi: 10.1530/EDM-23-0086. Print 2023 Oct 1.
本文引用的文献
1
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
2
Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.SGLT2 抑制剂对 2 型糖尿病患者尿路感染和生殖器感染的影响：系统评价和荟萃分析。
Sci Rep. 2017 Jun 6;7(1):2824. doi: 10.1038/s41598-017-02733-w.
3
Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.钠-葡萄糖协同转运蛋白2抑制剂对糖尿病酮症酸中毒的影响：一项随机对照试验的荟萃分析
Diabetes Res Clin Pract. 2017 Aug;130:53-60. doi: 10.1016/j.diabres.2017.04.017. Epub 2017 May 18.
4
Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.钠-葡萄糖协同转运蛋白2抑制剂卡格列净对2型糖尿病患者血压及动脉僵硬度标志物的影响：一项事后分析
Cardiovasc Diabetol. 2017 Feb 27;16(1):29. doi: 10.1186/s12933-017-0511-0.
5
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.达格列净可降低2型糖尿病患者的小而密低密度脂蛋白胆固醇水平，并升高高密度脂蛋白2胆固醇水平：与西格列汀的比较。
Cardiovasc Diabetol. 2017 Jan 13;16(1):8. doi: 10.1186/s12933-016-0491-5.
6
SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：对原发性文献中糖尿病酮症酸中毒及相关危险因素的系统评价
Pharmacotherapy. 2017 Feb;37(2):187-194. doi: 10.1002/phar.1881. Epub 2017 Jan 16.
7
Acute kidney injury from SGLT2 inhibitors: potential mechanisms.钠-葡萄糖协同转运蛋白2抑制剂所致急性肾损伤：潜在机制
Nat Rev Nephrol. 2016 Nov 16;12(12):711-712. doi: 10.1038/nrneph.2016.159.
8
Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.钠-葡萄糖协同转运蛋白2抑制剂对代谢的影响：未解决的问题与争议
Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):399-408. doi: 10.1080/17425255.2017.1258055. Epub 2016 Nov 17.
9
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.恩格列净抑制钠葡萄糖协同转运蛋白2对2型糖尿病患者微量白蛋白尿和大量白蛋白尿的影响。
Diabetologia. 2016 Sep;59(9):1860-70. doi: 10.1007/s00125-016-4008-2. Epub 2016 Jun 17.
10
Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.钠-葡萄糖协同转运蛋白2抑制剂诱导的正常血糖性糖尿病酮症酸中毒：可能机制及影响因素
J Diabetes Investig. 2016 Mar;7(2):135-8. doi: 10.1111/jdi.12401. Epub 2015 Sep 6.
Zotero 插件